Avacta looks set to reward an understanding of antibodies Financial Times Affimer is the sort of word that gives Aim a bad name. Investors are unaccustomed to grappling with a dictionary when trying to understand a company's business case. But Avacta, the animal health and biotechnology business, may be about to reward those ... |
